TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34762532

Group type: EXPERIMENTAL
Intervention: Low-level green laser (532 nm, 15 J/cm2 per treatment site)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Sodium fluoride (NaF) desensitizer
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo (distilled water and placebo laser)
Number of subjects: 48
Study: 32867996

Group type: EXPERIMENTAL
Intervention: Combined plant oils supplementation (POC)
Number of subjects: 720

Group type: COMPARATOR
Intervention: Control treatment (CON)
Number of subjects: 720

Group type: COMPARATOR
Intervention: Aureomycin supplementation (AGP)
Number of subjects: 720
Study: 36239176

Group type: EXPERIMENTAL
Intervention: Simultaneous implant placement
Number of subjects: 16

Group type: COMPARATOR
Intervention: Delayed implant placement (control)
Number of subjects: 16
Study: 32915276

Group type: EXPERIMENTAL
Intervention: AT LARA 829MP (EDOF)
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: TECNIS Symfony (EDOF)
Number of subjects: 211

Group type: COMPARATOR
Intervention: CT ASPHINA 409MP (monofocal)
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Both EDOF IOLs
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: All IOLs
Number of subjects: 211
Study: 32958076

Group type: EXPERIMENTAL
Intervention: Peer support intervention (8 weeks)
Number of subjects: 60
Study: 35477518

Group type: EXPERIMENTAL
Intervention: Iberdomide 0.45 mg
Number of subjects: 306

Group type: COMPARATOR
Intervention: Iberdomide (0.15 mg, 0.3 mg, 0.45 mg)
Number of subjects: 306
Study: 34922521

Group type: EXPERIMENTAL
Intervention: Cross-shaped incision technique in thick-gingiva group
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Cross-shaped incision technique in thin-gingiva group
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control (not explicitly mentioned)
Number of subjects: 55
Study: 34618017

Group type: EXPERIMENTAL
Intervention: Multiple arterial grafts (MAG)
Number of subjects: 1466

Group type: COMPARATOR
Intervention: Single arterial grafts (SAG)
Number of subjects: 1466

Group type: EXPERIMENTAL
Intervention: Multiple arterial grafts (MAG) in patients with three-vessel disease
Number of subjects: 1466

Group type: COMPARATOR
Intervention: Single arterial grafts (SAG) in patients with three-vessel disease
Number of subjects: 1466

Group type: EXPERIMENTAL
Intervention: Multiple arterial grafts (MAG) in patients with left main disease
Number of subjects: 1466

Group type: COMPARATOR
Intervention: Single arterial grafts (SAG) in patients with left main disease
Number of subjects: 1466
Study: 33323914

Group type: COMPARATOR
Intervention: Discordant treatment (DisTG)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Concordant treatment (ConTG)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Overall group (both DisTG and ConTG)
Number of subjects: 80
Study: 33295070

Group type: EXPERIMENTAL
Intervention: Modified wet suction technique (MWEST)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Dry suction technique (DST)
Number of subjects: 50
Study: 32275777

Group type: EXPERIMENTAL
Intervention: cilofexor
Number of subjects: 140

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 140
Study: 35820990

Group type: EXPERIMENTAL
Intervention: Universal school-based mindfulness training (SBMT)
Number of subjects: 679

Group type: COMPARATOR
Intervention: Teaching as usual (TAU)
Number of subjects: 679
Study: 34700768

Group type: EXPERIMENTAL
Intervention: Tumor Treating Fields (TTFields) with individualized array placement, delivering doses over 2.5 mW/cm3
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Transducer array layouts targeting the tumor
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Patient-specific treatment planning using numerical simulations
Number of subjects: 1
Study: 34984636

Group type: EXPERIMENTAL
Intervention: Medicaid coverage
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no Medicaid coverage)
Number of subjects: 0
Study: 34154034

Group type: EXPERIMENTAL
Intervention: GLE/PIB without ribavirin
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: GLE/PIB with ribavirin
Number of subjects: 32

Group type: COMPARATOR
Intervention: Treatment failure patients
Number of subjects: 32

Group type: COMPARATOR
Intervention: SVR12 achievers
Number of subjects: 32

Group type: COMPARATOR
Intervention: Retreatment with sofosbuvir-based regimens
Number of subjects: 32
Study: 32299254

Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Tramadol (50 mg)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156
Study: 36098201

Group type: EXPERIMENTAL
Intervention: 100 ppm chitosan nanoparticles
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 100 ppm silica nanoparticles
Number of subjects: 10
Study: 34138638

Group type: EXPERIMENTAL
Intervention: Imetelstat 9.4 mg/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Imetelstat 4.7 mg/kg
Number of subjects: 0
Study: 32304590

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 35718440

Group type: EXPERIMENTAL
Intervention: 1% curcumin nanomicelle gel
Number of subjects: 48

Group type: COMPARATOR
Intervention: 2% curcumin gel
Number of subjects: 48
Study: 34607863

Group type: EXPERIMENTAL
Intervention: Online chronic disease self-management programme (CDSMP) plus medication adherence tools
Number of subjects: 24

Group type: COMPARATOR
Intervention: Didactic lecture only
Number of subjects: 24
Study: 32756146

Group type: EXPERIMENTAL
Intervention: New method group (group A)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 200
Study: 35322981

Group type: EXPERIMENTAL
Intervention: Normal saline (5 mL)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Contrast medium (5 mL)
Number of subjects: 42
Study: 36449375

Group type: EXPERIMENTAL
Intervention: Subcutaneous fully closed-loop (FCL; CamAPS HX) insulin therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (UC) insulin therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison of FCL vs UC
Number of subjects: 0
Study: 33719017

Group type: EXPERIMENTAL
Intervention: Intranasal glulisine 20 IU twice daily
Number of subjects: 35

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 35
Study: 32612186

Group type: EXPERIMENTAL
Intervention: Avocado pulp (600 mg in capsule)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (600 mg starch in capsule)
Number of subjects: 16
Study: 32804855

Group type: EXPERIMENTAL
Intervention: 400 µg CrPic tablets (200 µg in two divided doses) daily for 12 weeks
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 33151727

Group type: EXPERIMENTAL
Intervention: Multidimensional forced-choice (MFC) format
Number of subjects: 1867

Group type: COMPARATOR
Intervention: Rating scale (RS) format
Number of subjects: 1867

Group type: EXPERIMENTAL
Intervention: MFC format with mixed triplets
Number of subjects: 1867

Group type: EXPERIMENTAL
Intervention: MFC format with fully matched triplets
Number of subjects: 1867
Study: 32087795

Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide 25 mg once a day
Number of subjects: 490

Group type: COMPARATOR
Intervention: Tenofovir disoproxil fumarate 300 mg once a day
Number of subjects: 490
Study: 32521121

Group type: EXPERIMENTAL
Intervention: Cinematic Rendering (CR)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Conventional Computed Tomography (CT)
Number of subjects: 16
Study: 34904748

Group type: EXPERIMENTAL
Intervention: Immunoadsorption (IA)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Therapeutic plasma exchange (TPE)
Number of subjects: 32
Study: 34009313

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MINT) sessions for 3 months
Number of subjects: 355

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 355
Study: 32080858

Group type: EXPERIMENTAL
Intervention: Cultured gingival fibroblasts (GF) on β‐calcium triphosphate (β‐TCP) scaffold covered by a collagen membrane.
Number of subjects: 20

Group type: COMPARATOR
Intervention: β‐calcium triphosphate (β‐TCP) followed by collagen membrane defect coverage.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cultured gingival fibroblasts (GF) on β‐TCP scaffold.
Number of subjects: 20
Study: 36578750

Group type: EXPERIMENTAL
Intervention: Platelet-rich fibrin matrix (PRFM) procedure done every 2 weeks with maximum three sittings
Number of subjects: 41

Group type: COMPARATOR
Intervention: Transplantation of autologous noncultured epidermal cell suspension (NCES) procedure done once
Number of subjects: 41
Study: 34648075

Group type: EXPERIMENTAL
Intervention: Limb remote ischaemic conditioning (RIC)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Control
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Limb remote ischaemic conditioning (RIC) in anterior STEMI subgroup
Number of subjects: 169

Group type: COMPARATOR
Intervention: Control in anterior STEMI subgroup
Number of subjects: 169
Study: 35843050

Group type: EXPERIMENTAL
Intervention: Inorganic nitrate intake (10 mmol potassium nitrate)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo drink (isomolar potassium chloride)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Inorganic nitrate intake
Number of subjects: 18
Study: 33406944

Group type: EXPERIMENTAL
Intervention: SAFETY program
Number of subjects: 0
Study: 33602890

Group type: EXPERIMENTAL
Intervention: Simultaneous reperfusion (SIM)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Primary portal vein reperfusion (PV)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Primary arterial reperfusion (A)
Number of subjects: 61
Study: 33065990

Group type: EXPERIMENTAL
Intervention: More intensive intervention
Number of subjects: 2294

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 2294
Study: 35680097

Group type: EXPERIMENTAL
Intervention: Adjuvant intravitreal therapy with 200 mg/ml 5-Fluorouracil (5-FU) and 5 IU/ml dalteparin (low-molecular weight heparin)
Number of subjects: 325

Group type: COMPARATOR
Intervention: Placebo (balanced salt solution)
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Adjuvant intravitreal therapy with 5-FU and LMWH
Number of subjects: 325
Study: 34710343

Group type: EXPERIMENTAL
Intervention: Icosapent ethyl 4 g daily
Number of subjects: 1837

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1837
Study: 32794478

Group type: EXPERIMENTAL
Intervention: Thumb spica cast with methylprednisolone acetate and xylocaine injection
Number of subjects: 134

Group type: COMPARATOR
Intervention: Thumb spica cast alone
Number of subjects: 134
Study: 33503393

Group type: EXPERIMENTAL
Intervention: Encorafenib plus Cetuximab plus Binimetinib (triplet)
Number of subjects: 665

Group type: EXPERIMENTAL
Intervention: Encorafenib plus Cetuximab (doublet)
Number of subjects: 665

Group type: COMPARATOR
Intervention: Control (irinotecan or FOLFIRI plus cetuximab)
Number of subjects: 665
Study: 32000772

Group type: EXPERIMENTAL
Intervention: Nintedanib
Number of subjects: 1061

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1061
Study: 35189911

Group type: EXPERIMENTAL
Intervention: Tourniquet group
Number of subjects: 28

Group type: COMPARATOR
Intervention: Non-tourniquet group
Number of subjects: 28
Study: 33141923

Group type: EXPERIMENTAL
Intervention: Firsocostat (FIR) 10 mg
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Firsocostat (FIR) 10 mg plus rifampin (RIF) 300 mg i.v.
Number of subjects: 28

Group type: COMPARATOR
Intervention: Rifampin (RIF) 300 mg i.v. (control)
Number of subjects: 28
Study: 35619144

Group type: EXPERIMENTAL
Intervention: Vacuum-assisted closure (VAC)
Number of subjects: 340

Group type: COMPARATOR
Intervention: Primary closure with relaparotomy on-demand (ROD)
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: VAC
Number of subjects: 340

Group type: COMPARATOR
Intervention: ROD
Number of subjects: 340
Study: 34047372

Group type: EXPERIMENTAL
Intervention: High dose genistein aglycone (160 mg/kg/day)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 36077269

Group type: EXPERIMENTAL
Intervention: Erythritol (10g, 25g, 50g)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Xylitol (7g, 17g, 35g)
Number of subjects: 17
Study: 33946072

Group type: EXPERIMENTAL
Intervention: Guided cognitive-behavioral web-based intervention (WBI) + treatment as usual (TAU)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 136
Study: 34301165

Group type: EXPERIMENTAL
Intervention: Supervised resistance training (EXE, n = 9)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Home-based stretching (STRETCH, n = 8)
Number of subjects: 17
Study: 33063780

Group type: EXPERIMENTAL
Intervention: Not applicable; no specific intervention mentioned.
Number of subjects: 0
Study: 32597672

Group type: EXPERIMENTAL
Intervention: Training with personalized corrective feedback
Number of subjects: 492

Group type: COMPARATOR
Intervention: Viewing and rating faces without feedback
Number of subjects: 492
Study: 33648819

Group type: EXPERIMENTAL
Intervention: Non-invasive brain stimulation combined with sensorimotor training
Number of subjects: 98
Study: 32304001

Group type: EXPERIMENTAL
Intervention: Non-surgical conventional treatment and diode laser application with wavelength of 980 nm (TG)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Non-surgical conventional treatment (CG)
Number of subjects: 23
Study: 34647482

Group type: EXPERIMENTAL
Intervention: Adult day services continued during the pandemic (telephone support, food delivery, medical check-ins, activities via Zoom/YouTube)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Closure of adult day services due to COVID-19
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Staffing changes due to COVID-19
Number of subjects: 22
Study: 35818840

Group type: COMPARATOR
Intervention: QI coaching
Number of subjects: 267

Group type: COMPARATOR
Intervention: Combined intervention (QI coaching + remote provider communication training)
Number of subjects: 267

Group type: COMPARATOR
Intervention: Remote communication training
Number of subjects: 267
Study: 33783390

Group type: EXPERIMENTAL
Intervention: Standardized capillary blood sampling protocol, staff education, randomized audits of heel-stick technique
Number of subjects: 0
Study: 32278939

Group type: EXPERIMENTAL
Intervention: Detour message only on the VMS
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Irrelevant VMS messages before the detour message
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Inconsistent detour message with destination
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (detour message only)
Number of subjects: 39
Study: 33438442

Group type: EXPERIMENTAL
Intervention: Gemcitabine with EPA-enriched oral supplement (1,000 mg/m2 gemcitabine on days 1, 8, and 15 every 4 weeks; EPA 1.056 mg per pack, maximum of two packs daily)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Gemcitabine monotherapy (1,000 mg/m2 on days 1, 8, and 15 every 4 weeks)
Number of subjects: 68
Study: 33526709

Group type: EXPERIMENTAL
Intervention: Sirukumab 100 mg SC every 2 weeks (q2w)
Number of subjects: 1820

Group type: EXPERIMENTAL
Intervention: Sirukumab 50 mg SC every 4 weeks (q4w)
Number of subjects: 1820

Group type: EXPERIMENTAL
Intervention: Both sirukumab dosages
Number of subjects: 1820
Study: 32267366

Group type: EXPERIMENTAL
Intervention: General obesity (BMI percentile ≥ 85)
Number of subjects: 486

Group type: EXPERIMENTAL
Intervention: Abdominal obesity (WC percentile > 90)
Number of subjects: 486

Group type: EXPERIMENTAL
Intervention: BMI percentile as a continuous variable
Number of subjects: 486

Group type: EXPERIMENTAL
Intervention: WC percentile as a continuous variable
Number of subjects: 486
Study: 35334418

Group type: EXPERIMENTAL
Intervention: Statin therapy (n = 824)
Number of subjects: 3420

Group type: EXPERIMENTAL
Intervention: Hydrophilic statins (n = 87)
Number of subjects: 3420

Group type: EXPERIMENTAL
Intervention: Hydrophilic statins in the denosumab arm
Number of subjects: 3420

Group type: EXPERIMENTAL
Intervention: Lipophilic statins (n = 710)
Number of subjects: 3420

Group type: EXPERIMENTAL
Intervention: Statin use
Number of subjects: 3420
Study: 34630613

Group type: EXPERIMENTAL
Intervention: Compound Shenlu granule (SLG) supportive group (group A, n = 44)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control group (group B, n = 45)
Number of subjects: 89
Study: 32933356

Group type: EXPERIMENTAL
Intervention: myo-inositol supplementation (2000 mg of myo-inositol and 200 μg of folic acid)
Number of subjects: 60
Study: 33043688

Group type: EXPERIMENTAL
Intervention: PrEP initiation and re-supply
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Peer adherence support
Number of subjects: 19
Study: 35653577

Group type: EXPERIMENTAL
Intervention: Intramuscular ketorolac 30 mg
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study: 34087482

Group type: EXPERIMENTAL
Intervention: HD-tDCS (high-definition transcranial direct current stimulation)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 50
Study: 33377611

Group type: EXPERIMENTAL
Intervention: Ranibizumab monthly regimen (0.5 mg) from baseline to Month 11
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Ranibizumab PRN regimen (0.5 mg) from Month 12 to Month 23
Number of subjects: 334
Study: 32232968

Group type: EXPERIMENTAL
Intervention: Mixed preservatives group
Number of subjects: 12454

Group type: EXPERIMENTAL
Intervention: 100% preservatives group
Number of subjects: 12454

Group type: COMPARATOR
Intervention: 0% preservatives group
Number of subjects: 12454
Study: 35321000

Group type: EXPERIMENTAL
Intervention: High-flow oxygen therapy
Number of subjects: 140

Group type: COMPARATOR
Intervention: General oxygen therapy
Number of subjects: 140
Study: 32043344

Group type: EXPERIMENTAL
Intervention: Carbohydrate-electrolyte solution (CES)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Carbohydrate-electrolyte-protein solution (CEPS)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Comparison between CES and CEPS
Number of subjects: 23
Study: 35848336

Group type: EXPERIMENTAL
Intervention: OCS‐01 (dexamethasone ophthalmic suspension), 1 drop 3 times/day for 12 weeks
Number of subjects: 144

Group type: COMPARATOR
Intervention: Vehicle (matching vehicle), 1 drop 3 times/day for 12 weeks
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: OCS‐01 (dexamethasone ophthalmic suspension)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Vehicle (matching vehicle)
Number of subjects: 144
Study: 32944843

Group type: EXPERIMENTAL
Intervention: GMB 120 mg
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: GMB 240 mg
Number of subjects: 270
Study: 35313932

Group type: EXPERIMENTAL
Intervention: Quarterly medical staff knowledge assessments using interactive vignettes with financial bonus payments for performance.
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control group (no financial incentives or knowledge assessments).
Number of subjects: 110
Study: 33243380

Group type: EXPERIMENTAL
Intervention: TMVr with the MitraClip plus guideline-directed medical therapy (GDMT) (n = 302)
Number of subjects: 614

Group type: COMPARATOR
Intervention: GDMT alone (n = 312)
Number of subjects: 614

Group type: EXPERIMENTAL
Intervention: TMVr with the MitraClip
Number of subjects: 614
Study: 34169381

Group type: EXPERIMENTAL
Intervention: Remote Ischemic Conditioning (RIC) administered daily for up to 15 days
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Remote Ischemic Conditioning (RIC)
Number of subjects: 55
Study: 35523505

Group type: EXPERIMENTAL
Intervention: Multi-nutrient supplement (330 kcal, 20 g protein, 1.5 g calcium 3-hydroxy-3-methylbutyrate monohydrate, 449 mg calcium, 500 IU vitamin D3, and 25 vitamins and minerals)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Multi-nutrient supplement
Number of subjects: 160

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 160
Study: 33466190

Group type: EXPERIMENTAL
Intervention: Hydrocolloid dressing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Polyurethane foam dressing
Number of subjects: 0
Study: 33563049

Group type: EXPERIMENTAL
Intervention: Combination of acupuncture and medical training therapy
Number of subjects: 95

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: All intervention groups (including acupuncture and medical training therapy)
Number of subjects: 95
Study: 32574352

Group type: EXPERIMENTAL
Intervention: Hypoxia challenge test (HCT) in T1D group
Number of subjects: 24

Group type: COMPARATOR
Intervention: Hypoxia challenge test (HCT) in control group
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Handgrip test in T1D group
Number of subjects: 24

Group type: COMPARATOR
Intervention: Handgrip test in control group
Number of subjects: 24
Study: 34224510

Group type: EXPERIMENTAL
Intervention: PO TXA (1.95 g 2 hours preoperatively)
Number of subjects: 261

Group type: COMPARATOR
Intervention: IV TXA (2 g: 1 g before incision and 1 g before wound closure)
Number of subjects: 261
Study: 34769944

Group type: EXPERIMENTAL
Intervention: Swim for Safety educational programme (12 lessons, face-to-face)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Control group (brochure and weekly mobile phone messages for six weeks)
Number of subjects: 156
Study: 32664090

Group type: EXPERIMENTAL
Intervention: Liquid sodium phosphocreatine cardiac arrest
Number of subjects: 84

Group type: COMPARATOR
Intervention: Conventional modified St Thomas II high potassium cold liquid crystal cardiac arrest
Number of subjects: 84
Study: 34740099

Group type: EXPERIMENTAL
Intervention: Virtual Reality Exposure Therapy (VRE)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Waitlist (WL)
Number of subjects: 44
Study: 33049708

Group type: EXPERIMENTAL
Intervention: Self‐mobilization (Self‐Mob)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Clinician‐applied Maitland talocrural joint mobilization
Number of subjects: 18
Study: 36469994

Group type: EXPERIMENTAL
Intervention: Ceasing opioid use
Number of subjects: 2473
Study: 34397057

Group type: EXPERIMENTAL
Intervention: Fermented rye bran (FRB)
Number of subjects: 84
Study: 33581014

Group type: EXPERIMENTAL
Intervention: HIIT (High-Intensity Interval Training)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: MIIT (Moderate-Intensity Interval Training)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 24
Study: 35546354

Group type: EXPERIMENTAL
Intervention: Bench step (BS) exercise for 10 minutes after acute mental stress (MS)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Rest (RE) for 10 minutes after acute mental stress (MS)
Number of subjects: 15